![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Généthon
Main focus: Gene therapies and gene editing for the treatment of genetic diseases
Company stage: Clinical
Diseases (gene editing): Sickle cell disease, beta-thalassemia, duchenne muscular dystrophy, lysosomal metabolic diseases
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Évry, Ile-de-France, France
Website: https://www.genethon.com/
Pipeline: https://www.genethon.com/our-therapies/
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_genethon_100dd73e01_229d681787.png)
Généthon is a French company focused on the development of gene therapies directed towards rare diseases. The company develops gene-editing based therapies as well as other types of gene therapies. Its gene-editing activities are centered around haematopoietic stem cells and blood disorders, such as sickle cell disease.